ClinicalTrials.gg
TerminatedNCT04004065MOMENTUMUpdated Mar 10, 2025

Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment

A Phase 2 interventional study of Vesleteplirsen in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Terminated at 25 sites in 8 countries. Open to male participants aged 7 Years to 21 Years. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by Sarepta Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
The study was terminated following review of safety data.

From the registry’s dates

  • Primary completion was Oct 2023, 3 years ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Oct 2024.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
7 Years to 21 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. — 5 open to participants now, 6 under way, 2 of them phase 3. Muscular Dystrophy, Duchenne · Sarepta Therapeutics, Inc..

Enrollment
9th of 25
62 · median 24
Started
2019
with 2 others
Phase 2
7 of 27
none open now
Registered
18th of 27
by date

Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 9th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2019, is one of 7 in phase 2, and was the 18th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

5 of the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 7 Years to 21 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., or all of them as a file.
02

Study summary

This study will be comprised of 2 parts: 1) Part A (Multiple Ascending Dose [MAD]) will be conducted to evaluate the safety and tolerability of vesleteplirsen at MAD levels to determine the maximum tolerated dose (MTD), and 2) Part B will be conducted to further evaluate the vesleteplirsen doses selected in Part A. Participants enrolling in Part B will be those who completed Part A or Study 5051-102 (NCT03675126) and meet applicable eligibility criteria for Part B, as well as additional participants who meet applicable eligibility criteria for enrollment at the beginning of Part B.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • DMD
  • Duchenne
  • Dystrophy
  • Dystrophin
  • Exon Skipping
  • Ambulatory
  • Duchenne Muscular Dystrophy
  • Exon 51
  • Nonambulatory
  • Pediatric
  • Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO)
04

Who can participate

Ages eligible
7 Years to 21 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for participants previously treated with Vesleteplirsen:

  • Has received prior Vesleteplirsen treatment in Part A of this study or in Study 5051-102.

Exclusion Criteria for participants previously treated with Vesleteplirsen and new participants enrolling into Part B:

  • Presence of other illness, including cardiac, pulmonary, hepatic, renal, hematologic, immunologic, or behavioral disease, or infection or or any other condition that, in the Investigator's opinion, could interfere with participation in the trial.

Inclusion Criteria for treatment-naïve participants enrolling into Part B:

  • Has a genetic diagnosis of Duchenne muscular dystrophy (DMD) and an out-of-frame deletion mutation of the DMD gene amenable to exon 51-skipping treatment.
  • Has been on a stable dose of oral for at least 12 weeks prior to study drug administration and the dose is expected to remain constant throughout the study (except for modifications to accommodate changes in weight), or has not received corticosteroids for at least 12 weeks prior to study drug administration.
  • Has stable pulmonary function (forced vital capacity [FVC] ≥40% of predicted and no requirement for nocturnal ventilation).

Exclusion Criteria for treatment-naive participants enrolling into Part B:

  • History of hypomagnesemia within 12 weeks prior to Screening.
  • Initiation or change of dosing (except for modifications to accommodate changes in weight or changes in standard of care) within 12 weeks prior to Screening for any of the following: angiotensin-converting enzyme inhibitors, angiotensin receptor-blocking agents, β-blockers, or potassium.
  • Initiation or change of dosing within 12 weeks prior to Screening for over-the-counter preparations, such as herbal/nonherbal supplements, vitamins, minerals, and homeopathic preparations.
  • Has a (LVEF) \<40.0% based on an echocardiogram (ECHO) performed within 12 weeks prior to Screening or at the Screening Visit.
  • Treatment with any exon 51-skipping therapy within 4 weeks prior to Screening, or with any experimental gene therapy for the treatment of DMD at any time.

Other inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Part A: Vesleteplirsen

    Participants received escalating dose levels of vesleteplirsen, every 4 weeks, via intravenous (IV) infusion for up to 75 weeks during Part A. Once the doses have been selected for Part B, all participants who have completed Part A will transition to Part B.

    Drug: Vesleteplirsen

  • Experimental
    Part B: Vesleteplirsen

    Participants received vesleteplirsen at the doses selected based on data from Part A every 4 weeks, via IV infusion, for up to 5 years. This included the participants who rolled over from Part A, as well as the additional participants who enrolled at the beginning of Part B.

    Drug: Vesleteplirsen

Interventions

  • Vesleteplirsen injection, for IV use

    Also known as: SRP-5051

06

What researchers measure

Primary outcomes

  1. Part A: Incidence of Adverse Events (AEs)

    Time frame: Part A: Baseline up to 75 weeks

  2. Part B: Change From Baseline in Dystrophin Protein Level at Week 28

    Time frame: Part B: Baseline, Week 28

Secondary outcomes

  1. Part A: Pharmacokinetics (PK): Plasma Concentration of Vesleteplirsen

    Time frame: Pre-dose and at multiple time points (up to 32 hours) after end of infusion

  2. Part A: PK: Urine Concentration of Vesleteplirsen

    Time frame: Pre-dose and at multiple time periods (up to 48 hours) after end of infusion

  3. Part B: Change From Baseline in Exon-Skipping Levels at Week 28

    Time frame: Part B: Baseline, Week 28

  4. Part B: Incidence of Adverse Events (AEs)

    Time frame: Part B: Baseline up to Week 304

  5. Part B: PK: Plasma Concentration of Vesleteplirsen

    Time frame: Part B predose and at multiple timepoints (up to 48 hours) after end of infusion

  6. Part B: PK: Urine Concentration of Vesleteplirsen

    Time frame: Part B predose and at multiple timepoints (up to 48 hours) after end of infusion

  7. Part B: Change from Baseline in Percent Dystrophin-Positive Fibers (PDPF) and Mean Intensity, as Measured by Immunofluorescence Assay at Week 28

    Time frame: Part B: Baseline, Week 28

07

Study locations

25 sites
  • University of California Davis Health
    Sacramento, California 95817, United States
  • Connecticut Children's
    Farmington, Connecticut 06032, United States
  • Northwest Florida Clinical Research Group, LLC
    Gulf Breeze, Florida 32561, United States
  • Rare Disease Research, LLC
    Atlanta, Georgia 30318, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center Research Inst.
    Kansas City, Kansas 66103, United States
  • University of Massachusetts
    Worcester, Massachusetts 01655, United States
  • UPMC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Austin Neuromuscular Center
    Austin, Texas 78756, United States
  • Children's Health Ambulatory Pavilion
    Dallas, Texas 75207, United States
  • Seattle Children's
    Seattle, Washington 98105, United States
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Children's Hospital - London Health Sciences Centre (LHSC)
    London, Ontario N6A 5W9, Canada
  • University of Essen - Children's Hospital
    Essen, D-45147, Germany
  • Klinikum der Universität München
    Munich, 80337, Germany
  • Fondazione Policlinico Universitario A Gemelli
    Rome, 168, Italy
  • A.O.U. Citta della Salute e della Scienza di Torino - SS Malattie Neuromuscolari, Department of Neurosciences
    Torino, 10139, Italy
  • Leiden University Medical Center
    Leiden, 2333, Netherlands
  • Hospital Sant Joan de Déu. U.B.
    Barcelona, 08950, Spain
  • Hospital Universitari I Politecnic La Fe de Valencia
    Valencia, 46026, Spain
  • Alder Hey Children's NHS Foundation Trust
    Liverpool, Lancashire L12 2AP, United Kingdom
  • Royal Hospital for Children (Glasgow)
    Glasgow, G51 4TF, United Kingdom
  • Great Ormond Street Hospital for Children NHS Foundation Trust
    London, WC1N 3JH, United Kingdom
  • Oxford University Hospial NHS Foundation Trust, John Radcliffe Hospital
    Oxford, OX3 9DU, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Oct 2023, 52 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2019
First posted
Jul 1, 2019
StartActual
Jun 26, 2019
Primary completionActual
Oct 30, 2023
CompletionActual
Feb 7, 2025
Results delay requested
Oct 28, 2024
Last update
Mar 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04004065
Responsible party
Sponsor
First posted
Jul 1, 2019
Start date
Jun 26, 2019
Primary completion
Oct 30, 2023
Completion
Feb 7, 2025
Last update
Mar 10, 2025

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vesleteplirsen

Start the discussion